Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: A multicenter, retrospective, observational study

Bone metastases are frequently observed in advanced cancer, and bone modifying agents are used to prevent or treat skeletal-related events. Zoledronic acid is contraindicated in patients with severe renal impairment (Ccr